Familial Cancer

Scope & Guideline

Connecting research and clinical practice in genetics.

Introduction

Welcome to the Familial Cancer information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Familial Cancer, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1389-9600
PublisherSPRINGER
Support Open AccessNo
CountryNetherlands
TypeJournal
Converge2001, from 2003 to 2024
AbbreviationFAM CANCER / Fam. Cancer
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

The journal 'Familial Cancer' focuses on the intersection of genetics and oncology, emphasizing inherited cancer syndromes and their implications for screening, diagnosis, and management. It aims to enhance understanding of familial cancer predispositions while promoting innovative research methodologies.
  1. Genetic predisposition to cancer:
    The journal emphasizes research on hereditary cancer syndromes, including the identification and characterization of genetic variants associated with increased cancer risk.
  2. Screening and surveillance strategies:
    A core area of focus is the development and evaluation of screening protocols for high-risk individuals, particularly those with familial cancer syndromes like Lynch syndrome and hereditary breast and ovarian cancer.
  3. Clinical management and interventions:
    The journal addresses clinical strategies for the management of hereditary cancers, including risk-reducing surgeries, chemoprevention, and personalized treatment approaches based on genetic profiles.
  4. Psychosocial aspects of genetic testing:
    Research on the psychological impact of genetic testing and the experiences of patients and families navigating hereditary cancer risk is an important theme, highlighting the need for supportive care.
  5. Policy and healthcare delivery:
    The journal also explores healthcare policy implications and the integration of genetic testing into clinical practice, focusing on improving access and equity in cancer care.
The landscape of research published in 'Familial Cancer' shows a dynamic evolution, with several themes emerging in recent years that reflect current challenges and advancements in the field.
  1. Integration of genomic technologies:
    Recent studies increasingly utilize advanced genomic techniques, such as whole genome sequencing and multi-gene panels, to identify hereditary cancer syndromes and characterize variants, reflecting the growing importance of precision medicine.
  2. Cascade testing and family communication:
    There is a rising emphasis on cascade genetic testing and the psychosocial dynamics of communicating genetic risk within families, highlighting the importance of family involvement in hereditary cancer management.
  3. Health disparities and access to care:
    Emerging themes include the examination of health disparities in access to genetic testing and cancer care, particularly among underrepresented populations, which is critical for equitable healthcare delivery.
  4. Long-term outcomes and survivorship:
    Studies focusing on long-term outcomes for individuals with hereditary cancer syndromes, including survivorship issues and quality of life, are becoming more prominent, addressing the holistic needs of patients post-diagnosis.
  5. Digital health innovations:
    The integration of digital health tools for cancer risk assessment and genetic counseling is a trending area of research, reflecting a shift towards technology-driven solutions in healthcare.

Declining or Waning

While the journal continues to explore a wide range of topics related to familial cancer, certain areas appear to be less frequently addressed in recent publications, indicating a potential decline in focus.
  1. Non-genetic factors in cancer risk:
    There has been a noticeable decrease in studies focusing on environmental or lifestyle factors contributing to familial cancer risk, suggesting a shift towards more genetic and molecular investigations.
  2. Rare cancer syndromes:
    Research on less common hereditary cancer syndromes, while still relevant, has seen a decline in frequency, as the journal's focus has increasingly gravitated towards more prevalent syndromes like Lynch syndrome and BRCA-related cancers.
  3. General population studies:
    The journal appears to be moving away from large-scale studies of general populations in favor of targeted research in specific high-risk groups, potentially reducing the breadth of its epidemiological coverage.

Similar Journals

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Advancing the Frontiers of Cancer Prevention
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1055-9965Frequency: 12 issues/year

Cancer Epidemiology Biomarkers & Prevention is a premier journal published by the American Association for Cancer Research, dedicated to advancing the understanding of cancer epidemiology, biomarkers, and preventive strategies. With an impressive impact factor that places it in the Q1 quartile across three critical categories — Epidemiology, Medicine, and Oncology — the journal stands as a vital resource for researchers and healthcare professionals seeking to explore novel insights in cancer prevention and control. The journal's rigorous selection process ensures the high quality of published research, making it a trusted source for the latest findings and methodologies in the fight against cancer. Although it currently does not support open access, the journal's comprehensive articles, spanning from its inception in 1983 to the present, facilitate significant advancements in the field. Located in Philadelphia, PA, this journal not only serves as a platform for dissemination but also stimulates vital discussions among the oncology community, ensuring that significant translational research reaches its audience effectively.

CA-A CANCER JOURNAL FOR CLINICIANS

Empowering Clinicians with Cutting-Edge Oncology Research
Publisher: WILEYISSN: 0007-9235Frequency: 6 issues/year

CA: A Cancer Journal for Clinicians is a prestigious academic journal published by Wiley, serving as a leading source of evidence-based information for those in the fields of oncology and hematology. With an impressive impact factor and ranked in the top quartile (Q1) for both specialties, this journal aims to bridge the gap between the latest research findings and clinical practice. Established in 1950, it boasts a long-standing history of delivering essential insights, guidelines, and innovative strategies to healthcare professionals worldwide, making significant contributions to the understanding and treatment of cancer. Although it does not offer open access, its published content is crucial for researchers, clinicians, and students dedicated to advancing cancer care. The journal's commitment to excellence is reflected in its elite rankings, holding the #1 position in both the Medicine – Oncology and Medicine – Hematology categories according to Scopus, positioning it in the 99th percentile of scholarly impact.

Lung Cancer Management

Empowering Clinicians with Cutting-Edge Findings
Publisher: FUTURE MEDICINE LTDISSN: 1758-1966Frequency: 4 issues/year

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Cancer Epidemiology

Illuminating the Path of Cancer Epidemiology
Publisher: ELSEVIER SCI LTDISSN: 1877-7821Frequency: 6 issues/year

Cancer Epidemiology, published by ELSEVIER SCI LTD, serves as a premier platform for disseminating innovative research in the areas of cancer epidemiology and oncology. Operating from the Netherlands, this journal provides a critical insight into the factors influencing cancer incidence, including genetic, environmental, and lifestyle variables. With an impact factor reflecting its significance in the field, it holds a respectable Q2 ranking in Cancer Research, Epidemiology, and Oncology. The journal spans a wide range of topics and publishes studies that aim to bridge gaps in existing literature through rigorous research methodologies. Researchers and professionals interested in acquiring the latest insights and contributing to the evolving discourse on cancer epidemiology will find this journal an invaluable resource. Access to articles may be available through open access options, ensuring the widest dissemination of knowledge.

CANCER CAUSES & CONTROL

Advancing Insights into Cancer Causes and Prevention
Publisher: SPRINGERISSN: 0957-5243Frequency: 12 issues/year

Cancer Causes & Control, an esteemed journal within the field of Cancer Research and Oncology, is published by SPRINGER. Since its inception in 1990, this journal has dedicated itself to exploring the complex interplay between environmental, genetic, and lifestyle factors that contribute to cancer causation and control, aiming to inform public health initiatives and improve cancer prevention strategies. With an impressive Q2 rank in both its categories, the journal serves as a vital resource for researchers, professionals, and students seeking insights into the latest findings and methodologies in cancer epidemiology. Although there is no Open Access option, researchers can access valuable articles that reflect rigorous peer review and significant contributions to the field. The journal’s commitment to advancing knowledge related to cancer risks and management makes it an essential platform for disseminating impactful research and fostering collaboration among scholars worldwide.

Cancer Prevention Research

Elevating the standards of cancer prevention research.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1940-6207Frequency: 12 issues/year

Cancer Prevention Research, published by the American Association for Cancer Research, is a leading journal dedicated to advancing our understanding of cancer prevention strategies and their implementation in public health. With an ISSN of 1940-6207 and E-ISSN 1940-6215, this journal serves as a pivotal platform for researchers, healthcare professionals, and students who are committed to unraveling the complexities of cancer etiology and preventive measures. Since its inception in 2008, the journal has carved a niche in the scientific community, achieving notable rankings including Q2 in Cancer Research and Q1 in both Medicine (miscellaneous) and Oncology, highlighting its significance in disseminating influential research. Cancer Prevention Research is indexed in Scopus, reflecting a robust impact factor, and features a range of articles that address the preventive aspects of cancer to promote healthier populations. With access options available, it invites contributions that bridge laboratory findings with epidemiologic insights, making it an essential resource for anyone dedicated to reducing the burden of cancer globally.

Chinese Journal of Cancer Research

Empowering researchers to combat cancer effectively.
Publisher: CHINESE JOURNAL CANCER RESEARCH COISSN: 1000-9604Frequency: 4 issues/year

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.

Genetics Research

Driving Progress in Genetic and Medical Sciences
Publisher: HINDAWI LTDISSN: 0016-6723Frequency: 1 issue/year

Genetics Research, published by HINDAWI LTD, is a distinguished open access journal that has been at the forefront of genetic studies since its inception in 1960. With the transition to open access in 2019, this journal has expanded its accessibility, fostering knowledge dissemination across the global scientific community. Operating out of the United Kingdom, it provides a platform for innovative research in the fields of genetics and molecular biology, encompassing a broad range of topics that are highly relevant to medical sciences. As of 2023, it holds a Q4 classification in Genetics and a Q3 classification in miscellaneous Medicine, reflecting its ongoing commitment to scholarly excellence amidst shifting academic landscapes. While the journal's H-index remains unlisted, its indexed ranking within Scopus, with a rank of #325/328 in the Genetics category highlights the challenges ligated to its niche audience. Nevertheless, it serves as a crucial resource for researchers, professionals, and students eager to contribute to and stay informed on the latest genetic research trends and breakthroughs.

CURRENT PROBLEMS IN CANCER

Bridging Gaps: Illuminating Current Problems in Cancer Management
Publisher: MOSBY-ELSEVIERISSN: 0147-0272Frequency: 6 issues/year

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.

Turk Onkoloji Dergisi-Turkish Journal of Oncology

Shaping the future of oncology with dedicated research and expertise.
Publisher: KARE PUBLISSN: 1300-7467Frequency: 4 issues/year

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.